
Summit Therapeutics Receives FDA Complete Response Letter on Ivonescimab Lung Cancer Application
The FDA said progression-free survival benefit without a statistically significant overall survival gain does not support approval.
Summit Therapeutics Inc. · Nasdaq · Pharmaceutical Preparations

The FDA said progression-free survival benefit without a statistically significant overall survival gain does not support approval.
No open-market insider buying or selling in the Form 4s filed since July 24, 2026.
Other events · Financial statements and exhibits
AI summary, unreviewedSummit Therapeutics Announces Planned Phase III HARMONi-10 Trial of Ivonescimab vs Durvalumab in Stage III NSCLC
Other events · Financial statements and exhibits
AI summary, unreviewedSummit Therapeutics Receives FDA Complete Response Letter for Ivonescimab BLA in Second-Line EGFR-Mutated NSCLC, Citing Lack of Statistically Significant Overall Survival Benefit